Have a feature idea you'd love to see implemented?
Let us know!
CARM Carisma Therapeutics Inc
Price (delayed)
$0.9597
Market cap
$39.87M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.74
Enterprise value
$3.27M
Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company's lead program, Vicineum™, also known as VB4-845, is
Highlights
The company's EPS has surged by 91% YoY and by 11% QoQ
CARM's gross profit has surged by 58% year-on-year and by 37% since the previous quarter
The equity has shrunk by 99% YoY and by 97% QoQ
Carisma Therapeutics's quick ratio has plunged by 60% YoY and by 40% from the previous quarter
Key stats
What are the main financial stats of CARM
Market
Valuations
Earnings
Shares outstanding
41.54M
Market cap
$39.87M
Enterprise value
$3.27M
Price to earnings (P/E)
N/A
Price to book (P/B)
110.75
Price to sales (P/S)
1.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.16
Revenue
$20.71M
EBIT
-$75.97M
EBITDA
-$65.3M
Free cash flow
-$76.51M
Per share
Balance sheet
Liquidity
EPS
-$1.74
Free cash flow per share
-$1.84
Book value per share
$0.01
Revenue per share
$0.5
TBVPS
$1.43
Total assets
$59.34M
Total liabilities
$58.98M
Debt
$3.76M
Equity
$360,000
Working capital
$35.1M
Debt to equity
10.44
Current ratio
3.25
Quick ratio
2.58
Net debt/EBITDA
0.56
Margins
Efficiency
Dividend
EBITDA margin
-315.3%
Gross margin
100%
Net margin
-350.1%
Operating margin
-366.8%
Return on assets
-88%
Return on equity
-344.9%
Return on invested capital
-969.9%
Return on capital employed
-173.8%
Return on sales
-366.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CARM stock price
How has the Carisma Therapeutics stock price performed over time
Intraday
9.65%
1 week
-0.64%
1 month
-4.98%
1 year
-77.78%
YTD
-67.25%
QTD
-2.23%
Financial performance
How have Carisma Therapeutics's revenue and profit performed over time
Revenue
$20.71M
Gross profit
$20.71M
Operating income
-$75.97M
Net income
-$72.5M
Gross margin
100%
Net margin
-350.1%
CARM's gross profit has surged by 58% year-on-year and by 37% since the previous quarter
The company's revenue has surged by 58% YoY and by 37% QoQ
The net margin has grown by 42% YoY and by 35% from the previous quarter
The operating margin is up by 37% year-on-year and by 35% since the previous quarter
Growth
What is Carisma Therapeutics's growth rate over time
Valuation
What is Carisma Therapeutics stock price valuation
P/E
N/A
P/B
110.75
P/S
1.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.16
The company's EPS has surged by 91% YoY and by 11% QoQ
The P/B is 131% more than the last 4 quarters average of 48.0
The equity has shrunk by 99% YoY and by 97% QoQ
The price to sales (P/S) is 84% lower than the 5-year quarterly average of 12.1 and 72% lower than the last 4 quarters average of 6.9
The company's revenue has surged by 58% YoY and by 37% QoQ
Efficiency
How efficient is Carisma Therapeutics business performance
The return on invested capital has dropped by 94% since the previous quarter
The return on equity has dropped by 74% year-on-year and by 60% since the previous quarter
CARM's ROA has dropped by 55% year-on-year and by 9% since the previous quarter
The company's return on sales rose by 38% YoY and by 35% QoQ
Dividends
What is CARM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CARM.
Financial health
How did Carisma Therapeutics financials performed over time
Carisma Therapeutics's quick ratio has plunged by 60% YoY and by 40% from the previous quarter
Carisma Therapeutics's total assets has shrunk by 55% YoY and by 20% QoQ
The equity has shrunk by 99% YoY and by 97% QoQ
The debt has contracted by 50% from the previous quarter and by 28% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.